Sialo Technology Israel Ltd. (TASE: SALO) has obtained US Food and Drug Administration (FDA) marketing approval for the company's modular endoscope for root canal, dental implants, and gum disease treatments. The endoscope enables direct viewing of the area of procedures for salivary gland, temporo-mandibular joint disorder (TMJ) of the jaw, and root canal treatments.
Marketing of the endoscope in the US is subject to the results of sterilization tests, which the company will conduct internally in the coming months. The FDA will have to approve these results as well, before marketing of the product.
Sialo has a non-exclusive marketing agreement for the endoscope and other products with Henry Schein Inc. (Nasdaq: HSIC).
Published by Globes [online], Israel business news - www.globes-online.com - on August 23, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments